As early as four weeks after the initiation of combined chemo/anti-PD1 therapy, an increase in circulating CX3CR1+ CD8+ T cells of at least 10 percent correlates with clinical benefit and positive ORR in patients with advanced NSCLC, and ultimately with improved survival [72]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.